Peptides for Nuclear Medicine

piCHEM develops and provides a wide range of molecules which are utilised as precursors for radiopharmaceuticals.

Precursors are used for:

• Targeted tumor diagnosis and therapy
• Non invasive examinations
• Receptor scintigraphy and therapy (PET)
• Development of cold kits
• Reference substances
• Development of new targeting molecules in close collaboration with radiopharmacy departments and nuclear medicine centers

Our comprehensive range of different diagnostic and therapeutic precursors and reference materials is available in different aliquot formulations with defined peptide content, as well as specific comparison materials for a wide range of metal impurities in tracer molecules.

Find out more about our Peptide Precursors here!

piCHEM is manufacturer of various peptides in the field of nuclear medicine and provides appropriate Chemistry, Manufacturing and Control (CMC) regulatory documents.

These documents contain important information and details of the production process to enable the competent authorities (including but not limited to EMA and FDA) to assess the manufacturing and control of the peptide. piCHEM will issue a letter of access (LoA) to allow relevant authorities to review the documents.

piCHEM actually holds DMF/ASMF for active ingredients:

DOTA-TOC (Edotreotid)

DOTA-TATE (Oxodotreotid)

HYNIC-TOC (INN not assigned)

PSMA-11 (Gozetotide)

PSMA I&T (INN not assigned)

piCHEM has a large expertise in filing regulatory documents for new chemical entities used in clinical trials and will support your submission in many countries throughout the world.